These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27939231)

  • 1. Effect of Pretransplant Continuous-Flow Left Ventricular Assist Devices on Cellular and Antibody-Mediated Rejection and Subsequent Allograft Outcomes.
    Nestorovic EM; Grupper A; Joyce LD; Milic NM; Stulak JM; Edwards BS; Pereira NL; Daly RC; Kushwaha SS
    Am J Cardiol; 2017 Feb; 119(3):452-456. PubMed ID: 27939231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac allograft rejection in the current era of continuous flow left ventricular assist devices.
    Bakir NH; Finnan MJ; MacGregor RM; Schilling JD; Ewald GA; Kotkar KD; Itoh A; Damiano RJ; Moon MR; Masood MF
    J Thorac Cardiovasc Surg; 2022 Jan; 163(1):124-134.e8. PubMed ID: 33012541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between bridging with ventricular assist device on rejection after heart transplantation.
    Pamboukian SV; Costanzo MR; Dunlap S; Rayburn B; Westfall AO; You ZY; Hung E; McLeod M; Heroux A
    J Heart Lung Transplant; 2005 Mar; 24(3):310-5. PubMed ID: 15737758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant.
    Ko BS; Drakos S; Kfoury AG; Hurst D; Stoddard GJ; Willis CA; Delgado JC; Hammond EH; Gilbert EM; Alharethi R; Revelo MP; Nativi-Nicolau J; Reid BB; McKellar SH; Wever-Pinzon O; Miller DV; Eckels DD; Fang JC; Selzman CH; Stehlik J;
    J Heart Lung Transplant; 2016 Aug; 35(8):1024-30. PubMed ID: 27316382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of age on outcomes following continuous-flow left ventricular assist device implantation.
    Lushaj EB; Badami A; Osaki S; Murray M; Leverson G; Lozonschi L; Akhter S; Kohmoto T
    Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):743-8. PubMed ID: 25770085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Continuous-Flow Left Ventricular Assist Device Duration on Postoperative Outcomes.
    Chauhan D; Okoh AK; Haik N; Kang N; Choi M; Baran D; Zucker M; Camacho M; Russo MJ
    Ann Thorac Surg; 2017 Dec; 104(6):1933-1938. PubMed ID: 28964413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of angiotensin II type 1 receptor antibodies on post-heart transplantation outcome in Heart Mate II bridged recipients.
    Urban M; Slavcev A; Gazdic T; Ivak P; Besik J; Netuka I
    Interact Cardiovasc Thorac Surg; 2016 Mar; 22(3):292-7. PubMed ID: 26675563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allograft rejection in patients supported with continuous-flow left ventricular assist devices.
    Healy AH; Mason NO; Hammond ME; Reid BB; Clayson SE; Drakos SG; Kfoury AG; Patel AN; Bull DA; Budge D; Alharethi RA; Bader FM; Gilbert EM; Stehlik J; Selzman CH
    Ann Thorac Surg; 2011 Nov; 92(5):1601-7; discussion 1607. PubMed ID: 21944258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosensitization in bridge to transplant Novacor left ventricular assist device patients: analysis of long-term outcomes with regard to acute rejection and chronic allograft vasculopathy.
    Kirsch L; Timmermans T; Van Caenegem O; Gurne O; Noirhomme P; Jacquet LM; Latinne D; Poncelet AJ
    Eur J Cardiothorac Surg; 2008 Aug; 34(2):268-74; discussion 274. PubMed ID: 18456505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of pretransplant HeartMate II left ventricular assist device placement and heart transplantation mortality.
    Donneyong M; Cheng A; Trivedi JR; Schumer E; McCants KC; Birks EJ; Slaughter MS
    ASAIO J; 2014; 60(3):294-9. PubMed ID: 24614355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival.
    Pagani FD; Dyke DB; Wright S; Cody R; Aaronson KD
    J Heart Lung Transplant; 2001 Jun; 20(6):646-53. PubMed ID: 11404170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes after heart transplantation in sensitized patients bridged with ventricular assist devices.
    Fraser CD; Zhou X; Magruder JT; Suarez-Pierre A; Lui C; Grimm JC; Higgins R; Kilic A
    J Card Surg; 2019 Jun; 34(6):474-481. PubMed ID: 31045281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation With Continuous-Flow Left Ventricular Assist Devices.
    Asleh R; Alnsasra H; Daly RC; Schettle SD; Briasoulis A; Taher R; Dunlay SM; Stulak JM; Behfar A; Pereira NL; Frantz RP; Edwards BS; Clavell AL; Kushwaha SS
    J Am Heart Assoc; 2019 Nov; 8(22):e013108. PubMed ID: 31701791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous-flow left ventricular assist device therapy in patients with preoperative hepatic failure: are we pushing the limits too far?
    Weymann A; Patil NP; Sabashnikov A; Mohite PN; Garcia Saez D; Bireta C; Wahlers T; Karck M; Kallenbach K; Ruhparwar A; Fatullayev J; Amrani M; De Robertis F; Bahrami T; Popov AF; Simon AR
    Artif Organs; 2015 Apr; 39(4):336-42. PubMed ID: 25345547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation.
    Raichlin E; Edwards BS; Kremers WK; Clavell AL; Rodeheffer RJ; Frantz RP; Pereira NL; Daly RC; McGregor CG; Lerman A; Kushwaha SS
    J Heart Lung Transplant; 2009 Apr; 28(4):320-7. PubMed ID: 19332257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic sensitization in recipients of left ventricular assist devices.
    John R; Lietz K; Schuster M; Naka Y; Rao V; Mancini DM; Rose EA; Smith CR; Oz MC; Edwards NM; Itescu S
    J Thorac Cardiovasc Surg; 2003 Mar; 125(3):578-91. PubMed ID: 12658200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does renal dysfunction and method of bridging support influence heart transplant graft survival?
    Haglund NA; Feurer ID; Dwyer JP; Stulak JM; DiSalvo TG; Keebler ME; Schlendorf KH; Wigger MA; Maltais S
    Ann Thorac Surg; 2014 Sep; 98(3):835-41. PubMed ID: 25069689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial Arrhythmias and Electroanatomical Remodeling in Patients With Left Ventricular Assist Devices.
    Deshmukh A; Kim G; Burke M; Anyanwu E; Jeevanandam V; Uriel N; Tung R; Ozcan C
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28275069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab.
    Lick SD; Beckles DL; Piovesana G; Vaidya S; Indrikovs A; Barbagelata NA; Valentine V
    Ann Thorac Surg; 2011 Oct; 92(4):1428-34. PubMed ID: 21855854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ventricular reconditioning and pump explantation in patients supported by continuous-flow left ventricular assist devices.
    Frazier OH; Baldwin AC; Demirozu ZT; Segura AM; Hernandez R; Taegtmeyer H; Mallidi H; Cohn WE
    J Heart Lung Transplant; 2015 Jun; 34(6):766-72. PubMed ID: 25447571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.